$0.13 EPS Expected for PDL BioPharma Inc (PDLI)

October 28, 2017 – By Peter Erickson

Investors sentiment decreased to 0.8 in 2017 Q2. Its down 0.06, from 0.86 in 2017Q1. It worsened, as 13 investors sold PDL BioPharma Inc shares while 58 reduced holdings. 21 funds opened positions while 36 raised stakes. 123.93 million shares or 1.80% less from 126.21 million shares in 2017Q1 were reported.
First Republic Investment Management holds 0% in PDL BioPharma Inc (NASDAQ:PDLI) or 142,097 shares. Massachusetts-based Wellington Group Inc Limited Liability Partnership has invested 0% in PDL BioPharma Inc (NASDAQ:PDLI). Retail Bank Of America De has 1.81M shares. Virginia Retirement System Et Al holds 0% of its portfolio in PDL BioPharma Inc (NASDAQ:PDLI) for 52,400 shares. Cornerstone Capital Mgmt Holding Ltd Llc accumulated 145,496 shares. Ameritas Investment Prtnrs stated it has 12,664 shares or 0% of all its holdings. Kestrel Investment Mgmt Corp, a California-based fund reported 1.74M shares. Employees Retirement Systems Of Ohio owns 65,612 shares. Savings Bank Of Montreal Can holds 390,186 shares. Millennium Mngmt Ltd Co has invested 0% of its portfolio in PDL BioPharma Inc (NASDAQ:PDLI). Ironwood Fincl Ltd Liability holds 1,150 shares. Moreover, Nine Chapters Ltd Liability has 0.87% invested in PDL BioPharma Inc (NASDAQ:PDLI). Mckinley Mngmt Limited Liability Corp Delaware invested in 0.03% or 323,608 shares. Loring Wolcott And Coolidge Fiduciary Advsr Limited Liability Partnership Ma owns 0% invested in PDL BioPharma Inc (NASDAQ:PDLI) for 500 shares. Oppenheimer Inc invested 0% of its portfolio in PDL BioPharma Inc (NASDAQ:PDLI).

Analysts expect PDL BioPharma Inc (NASDAQ:PDLI) to report $0.13 EPS on November, 2.They anticipate $0.02 EPS change or 18.18 % from last quarter’s $0.11 EPS. PDLI’s profit would be $20.03 million giving it 5.87 P/E if the $0.13 EPS is correct. After having $0.26 EPS previously, PDL BioPharma Inc’s analysts see -50.00 % EPS growth. The stock increased 3.04% or $0.09 during the last trading session, reaching $3.05. About 1.86M shares traded. PDL BioPharma Inc (NASDAQ:PDLI) has declined 26.03% since October 28, 2016 and is downtrending. It has underperformed by 42.73% the S&P500.

PDL BioPharma Inc (NASDAQ:PDLI) Ratings Coverage

Among 3 analysts covering PDL BioPharma (NASDAQ:PDLI), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. PDL BioPharma had 7 analyst reports since October 16, 2015 according to SRatingsIntel. The stock of PDL BioPharma Inc (NASDAQ:PDLI) has “Sector Perform” rating given on Tuesday, February 23 by RBC Capital Markets. The company was maintained on Thursday, December 22 by PiperJaffray. As per Tuesday, February 2, the company rating was maintained by RBC Capital Markets. Cowen & Co maintained PDL BioPharma Inc (NASDAQ:PDLI) rating on Friday, August 4. Cowen & Co has “Hold” rating and $300 target. On Thursday, November 5 the stock rating was maintained by RBC Capital Markets with “Sector Perform”. The company was maintained on Friday, October 16 by RBC Capital Markets.

PDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The company has market cap of $469.95 million. The Company’s divisions include income generating assets and product sales. It has a 6.74 P/E ratio. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments.

Another recent and important PDL BioPharma Inc (NASDAQ:PDLI) news was published by Marketwatch.com which published an article titled: “PDL BioPharma makes unsolicited bid to buy Neos Therapeutics for a 40% premium” on October 26, 2017.